Efficacy of PIASKLEDIN® 300 in patients with primary knee and hip osteoarthritis

Bortkevych O.P. ¹, Korendovych V.V.², Bilyavska Yu.V.

• ¹SI «NSC «Institute of Cardiology M.D. Strazhesko» NAMS of Ukraine», Kyiv
• ²ДУ «Національний науковий центр «Інститут кардіології ім. М.Д. Стражеска» НАМН України», Київ

Summary. Efficacy and tolerability of Piaskledin® 300 in patients with primary knee and hip osteoarthritis of I–III radiographic stage with clinically significant disease manifestations are highlighted in prospective study. As efficacy indicators were selected pain intensity at rest and during movement, morning stiffness duration and intensity, Lequesne index, the WOMAC index, the daily need for non-steroidal anti-inflammatory drugs and an individual assessment of the treatment effectiveness. Drug side effects were also analyzed. According to the data received, the majority of patients showed a significant decrease of pain intensity at rest and during movement, morning stiffness duration and intensity, as well as values of the total Lequesne and WOMAC indicies. As a result Piaskledin® 300 confirmed to be an effective and safe drug with symptom-modifying effects which has a good tolerability, the minimal contraindications and positive compliance.